ANVS

Annovis Bio, Inc. [ANVS] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

ANVS Stock Summary

Top 10 Correlated ETFs

ANVS

Top 10 Correlated Stocks

ANVS

In the News

ANVS Financial details

Company Rating
-
Market Cap
128.06M
Income
-75.91M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
6
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-2.07
Forward P/E
-
PEG
-0.12
P/S
-
P/B
17.62
P/C
-
P/FCF
-4.27
Quick Ratio
1.78
Current Ratio
2.87
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-8.62
EPS next Y
-
EPS next Q
-
EPS this Y
102.27%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
42.94%
-
-
-
-
SMA20
17.51%
SMA50
102.38%
SMA100
-43.71%
Inst Own
-
Inst Trans
-
ROA
-555%
ROE
-299%
ROC
-2.65%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
5.42-22.49
52W High
-90.68%
52W Low
-59%
RSI
41.1
Rel Volume
1.8
Avg Volume
244.62K
Volume
440.44K
Perf Week
-22.05%
Perf Month
21.3%
Perf Quarter
-59.88%
Perf Half Y
-61.1%
-
-
-
-
Beta
1.589
-
-
Volatility
0.32%, 0.43%
Prev Close
-5.53%
Price
2.05
Change
-10.09%

Something similar

Top by Market Cap
CMC.DE
TSLA
MSFT
BRK-B
AAPL
Top Correlated ETFs
GOEX
SPRE
JNUG
GBUG
GDXJ
Top Correlated Stocks
0IIW.L
ETSY
PETZ
RPTX
001630.KS
Similar Market Cap
TROO
LMKG.ST
0954.HK
XSPD.L
EPIS-B.ST

Company Profile

Healthcare Biotechnology
  • Volume Average 244.62K
  • Market Capitalization 128.06M
  • Employee 6
  • CEO Dr. Maria L. Maccecchini Ph.D.
  • Headquarters Berwyn,PA,US
  • IPO Date 2020-01-29
  • Website https://www.annovisbio.com

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.